3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Leukemia, Myeloid, Acute
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Hematologic Neoplasms
4
Neoplasms
2
Lymphoma, Non-Hodgkin
2
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Lymphoproliferative Disorders
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia
1
Interventions
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
Vemurafenib
2
trametinib
1
pertuzumab
1
dabrafenib
1
atezolizumab
1
abexinostat
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
atezolizumab
×
Other hematologic neoplasm
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled